Ingrid Sophie Marianne Rayez

LBO France Gestion SAS (LBO France) is one of the oldest independent private equity firms in France. Established in 1985, the firm manages leveraged buyout transactions through their small-cap, mid-cap and real estate funds. Headquartered in Paris, LBO France primarily targets French firms or companies which are based or which transact most of their business in France.

Entrepreneurs et Investisseurs Technologies SA specializes in the sector of consulting in computer systems and software. The company is headquartered in Levallois-perret, France.

Innovation Capital SASU (Innovation Capital) is the international venture capital subsidiary of CDC Capital Investissement SAS, itself a wholly-owned subsidiary of State-owned CDC Caisse des Dépôts et Consignations in France. Established in 1996 as CDC Entreprises Innovation, the firm was formerly known as CDC Innovation SASU. They changed their name to Innovation Capital SASU in 2012. Located in Paris with representative offices in California and in Switzerland, the firm manages venture capital and innovation mutual funds (FCPRs and FCPIs). Their venture capital funds are sponsored by CDC Capital Investissement, and the innovation funds are generally co-invested with the venture capital funds. The firm's mandate includes public interest missions.

Bioring SA is a venture-backed company which designs, develops and markets new biodegradable medical devices and implants improving treatment outcome and reducing post treatment risk and complications. The Company's products originate from a proprietary know-how in chemical engineering and manufacturing which results in a unique technology platform combined with an expertise in medical device design and development. The Company's products find applications across the board, with a primary focus on cardiac surgery and urology. They can be implanted in standard open surgery as well as minimally invasive surgery, with or without a catheter. Bioring is funded by CDC Innovation, a leading French venture capital group, in addition to a number of business angels. The Company has taken its first product to the market in cardiac surgery in 2005 and has ongoing developments of other cardiac devices as well as promising urology products. Each one of these products addresses an opportunity of several hundred million dollars. Cardiac surgery The biodegradable Kalangos Rings for mitral and tricuspid valvuloplasty in adults and children is CE marked Cardiology Biodegradable stents for coronary arteries: in development Biodegradable membranes and support for percutaneous patent foramen ovale occlusion: in development Urology Biodegradable stents for male urethral implantation: in development Biodegradable prostheses for female urinary incontinence (FUI): in development